

Budesonide/Glycopyrrolate/Formoterol (BREZTRI) Inhaler

Criteria for Use

September 2021

VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives

The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. THE CLINICIAN SHOULD USE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT. INDIVIDUAL CASES THAT ARE EXCEPTIONS TO THE EXCLUSION AND INCLUSION CRITERIA SHOULD BE ADJUDICATED AT THE LOCAL FACILITY ACCORDING TO THE POLICY AND PROCEDURES OF ITS P&T COMMITTEE AND PHARMACY SERVICES.

The Product Information should be consulted for detailed prescribing information.

Abbreviations: FEV1/FVC=ratio of forced expiratory volume in the first one second to forced vital capacity; ICS=inhaled corticosteroid; LABA=long-acting beta-agonist; LAMA=long-acting muscarinic antagonists

Exclusion Criteria

- Diagnosis of asthma

Inclusion Criteria

The answers to ALL of the following must be fulfilled in order to meet criteria.

- Initial prescription is by or in consult with a VA/VA Community Care pulmonologist or designated expert
- Diagnosis of chronic obstructive pulmonary disease (post-bronchodilator ratio of FEV1/FVC less than 70%)
- Receiving ICS/LABA or LAMA/LABA but requires additional maintenance treatment for uncontrolled COPD symptoms and/or exacerbations¹
- If currently receiving an ICS, patient is NOT a candidate for ICS de-escalation

Additional Inclusion Criteria

AND at least ONE of the following:

- Documented difficulty adhering to 3-drug therapy via 2 separate inhalers (ICS/LABA + LAMA or LABA/LAMA + ICS)²
- Unable to use multiple inhalers due to underlying conditions (e.g., cognitive deficits, dexterity or visual impairment, etc.)
- Uncontrolled COPD symptoms and/or exacerbations while using formulary LABA/LAMA + ICS or ICS/LABA + LAMA²

¹Criterion does not apply to patients already using 3 different/separate inhalation products (see criteria below)

²Assess adherence and inhaler technique and provide any needed patient education before switching to Breztri

Patients doing well on 3-drug therapy via 2 separate inhalers should not be switched solely for convenience. These cases should be adjudicated on a case-by-case basis